Related Experiment Video

Updated: Jul 22, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.0K

Novel insight into RNA modifications in tumor immunity: Promising targets to prevent tumor immune escape

Yuxin Kong1, Jie Yu1, Shengfang Ge1

  • 1Department of Ophthalmology, Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai 200001, China.

Innovation (Cambridge (Mass.))
|July 24, 2023
PubMed

Insights

RNA modifications like m6A, m1A, and m5C are crucial in tumor immunity, impacting immune cells and tumor cells. Targeting these epigenetic changes shows promise for overcoming resistance to immune checkpoint inhibitor (ICI) therapy.

Area of Science:

  • Immunology
  • Epigenetics
  • Oncology

Background:

  • Tumor microenvironments are typically immunosuppressive, limiting the effectiveness of immune checkpoint inhibitor (ICI) therapy.
  • Epigenetic modifications play a key role in tumor immune regulation, with recent trials showing improved ICI outcomes with epigenetic drugs.
  • RNA modifications, including N6-methyladenosine (m6A), N1-methyladenosine (m1A), and 5-methylcytosine (m5C), are emerging as critical factors in tumor immunity.

Purpose of the Study:

  • To provide a comprehensive understanding of the roles of m6A, m1A, and m5C in tumor immunity.
  • To elucidate the mechanisms by which these RNA modifications regulate immune cells and tumor cells.
  • To discuss current strategies targeting RNA modifications for cancer immunotherapy.

Main Methods:

  • Review of current literature on RNA modifications and tumor immunity.
  • Analysis of mechanisms including immune checkpoint modulation, metabolic reprogramming, and immune factor secretion.
  • Discussion of therapeutic strategies targeting RNA modifications.

Main Results:

  • m6A, m1A, and m5C directly regulate immune cells and indirectly affect tumor cells.
  • These RNA modifications influence immune checkpoints, cellular metabolism, and the secretion of immune-related factors.
  • Targeting RNA modifications offers potential to overcome resistance to ICI therapy.

Conclusions:

  • RNA modifications are critical regulators of the tumor immune response.
  • Understanding these epigenetic mechanisms is key to developing novel cancer immunotherapies.
  • Targeting RNA modifications presents a promising strategy to enhance ICI therapy efficacy and prevent tumor immune escape.

More Related Videos

Author Spotlight: Exploring Strategies for Successful Immune Response Against Tumors05:58

Author Spotlight: Exploring Strategies for Successful Immune Response Against Tumors

Published on: August 16, 2024

2.9K
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

13.8K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
560
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
977